Objective-Chymase released by activated mast cells degrades high-density lipoproteins. We evaluated whether local activation of mast cells would attenuate cholesterol efflux from neighboring macrophage foam cells, thereby disrupting the entire in vivo pathway of macrophage-specific reverse cholesterol transport (RCT). Methods and Results-C57Bl/6J mice received intraperitoneal injections of the mast cell-degranulating compound 48/80
B
y promoting efflux of cholesterol from macrophages, high-density lipoproteins (HDL) attenuate the formation of foam cells, a hallmark of atherogenesis. 1 Efflux of cellular cholesterol initiates reverse cholesterol transport (RCT), a multistep process that facilitates the transfer of cholesterol from peripheral locations to the liver and finally to feces, thus providing a major pathway for elimination of excess cholesterol from the body. 2 Indeed, initiation of RCT from cholesterolloaded macrophages in the arterial intima counteracts the formation of atherosclerotic lesions. 3 Multiple studies have highlighted the key role of apolipoprotein A-I (apoA-I) structure-function relationships on the efficiency of HDL particles at promoting cholesterol efflux and in subsequent steps of RCT. 4 Moreover, modulation of the macrophagedependent RCT pathway has been recently achieved by structural and conformational modifications of apoA-I. 5 Importantly, the finding of circulating HDL with attenuated antiatherogenic function in subjects with atherosclerosis reinforced the concept that dysfunctional HDL particles are generated in vivo and may predict cardiovascular risk. 6 Mast cells are a potent source of neutral serine proteases. 7 In the arterial intima, mast cells have been found in close proximity to macrophage foam cells. 8 We have demonstrated that mast cell-derived chymase is able to modify HDL particles in vitro, thereby attenuating their ability to function as cholesterol acceptors. 9 Activation of peritoneal mast cells, with ensuing exocytosis of chymase-containing granules (degranulation), also blocked cholesterol release from cholesterol-loaded macrophages generated in the peritoneal cavity of the rat. 9 This suggested a role for mast cell proteases in the in vivo inhibition of RCT. Moreover, we found recently that systemic activation of mast cells by induction of anaphylactic shock in the mouse caused a mast cell-dependent proteolytic modification of HDL particles. 10 This in turn compromised the ability of mouse serum and peritoneal fluid to act as cholesterol acceptors in macrophage foam cell cultures. Mast cell-derived chymotryptic activity was the factor generating dysfunctional HDL particles in the anaphylactic mouse. Among the mouse mast cell proteases, only mouse mast cell protease-4, the functional homologue of human chymase, remains heparin proteoglycan bound after secretion from activated mast cells, which protects it from inactivation by physiological inhibitors present in the extracellular fluids. 11, 12 Consequently, this enzyme was most likely responsible for the proteolytic modification of HDL particles and the degradation of apolipoprotein E observed during systemic anaphylaxis in the mouse. 10 In support of the antiatherogenic role of apoA-I in humans, 13, 14 overexpression of human apoA-I in mice has been shown to increase RCT along the pathway from macrophages injected in the peritoneal cavity to feces. 15, 16 Here, to evaluate the effect of mast cell activation on the apolipoproteinmediated stimulation of macrophage RCT, we stimulated RCT by injecting human apoA-I and cholesterol-labeled macrophage foam cells into the mouse peritoneal cavity, a body compartment rich in resident mast cells. We then evaluated whether local activation of peritoneal mast cells would affect this stimulatory effect of apoA-I on RCT. This strategy allowed us to demonstrate that tissue-specific activation of mast cells is able to inhibit the macrophage RCT pathway via proteolytic inactivation of the physiological acceptors of macrophage-derived cholesterol, notably apoA-I.
Materials and Methods
A detailed description of the animals, materials, and methods used in the present study is provided in the Supplemental Material, available online at http://atvb.ahajournals.org. A brief description of the methods is given below.
C57Bl/6J mast cell-competent and mast cell-deficient W-sash c-kit mutant Kit W-sh/W-sh mice created on the C57Bl/6J background, which lack mature mast cells because of an inversion mutation of the c-Kit promoter region, were used. Lipid-free human apoA-I was degraded by chymase-containing mouse peritoneal mast cell lysates in vitro or exposed to activated peritoneal mast cells in vivo. The ability of the proteolyzed apoA-I to act as a cholesterol acceptor was evaluated in mouse macrophage foam cell cultures, and its ability to stimulate macrophage RCT was determined in vivo. A validated in vivo macrophage-specific RCT assay was applied to assess the rate of RCT in mast cell-competent and mast cell-deficient mice within 3 hours. For the RCT protocol, mice received consecutive intraperitoneal injections of (1) the mast cell-specific degranulating compound 48/80 (1 mg/kg) to achieve immediate local activation of peritoneal mast cells (stimulated group) or saline (nonstimulated group) and (2) human apoA-I (3 mg/kg) together with [ 3 H]cholesterol-labeled J774 macrophages, and the rate of RCT was measured after 3 hours of the macrophage injection. In other RCT experiments, mice received intraperitoneal doses of chymase-treated apoA-I (3 mg/kg) or phospholipid vesicles (30 mg/kg) together with the [ 3 H]cholesterol-labeled macrophages. Plasma lipoproteins were fractionated by fast protein liquid chromatography using a Superose 6R column. Pre-␤-and ␣-HDL subpopulations were detected by 2-dimensional immunoelectrophoresis. GraphPad Prism 4.0 software was used for all statistical analyses. Probability values Ͻ0.05 were considered statistically significant.
Results

In Vitro Proteolytic Inactivation of Human ApoA-I by Mouse Chymase
We first evaluated whether mouse mast cell chymase, like human chymase, 17 would proteolyze lipid-free human apoA-I in vitro. For this purpose, we exposed apoA-I to increasing chymase activities by incubating it with increasing amounts of either chymase-containing lysate derived from mouse peritoneal mast cells or recombinant human chymase. After 3 hours, the proteolytic profile of apoA-I was evaluated by SDS-PAGE. An efficient degradation of apoA-I was observed already at the lowest chymase activity (2 units) with generation of 2 fragments with apparent molecular masses of 26 and 24 kDa ( Figure 1A ). The intensities of both polypeptide bands gradually declined with increasing chymase activity, the decline of the 26-kDa band being faster than that of the 24-kDa band. Incubation with mouse chymase led to total loss of the intact apoA-I band at 10 units, whereas human chymase appeared to deplete intact apoA-I already at 2 units. Importantly, the proteolytic profiles of human apoA-I generated by both chymases were very similar.
Next, we evaluated the ability of the apoA-I proteolytic fragments to act as acceptors of macrophage cholesterol. For Figure 1 . In vitro mast cell-dependent proteolytic inactivation of human apoA-I. A, Human apoA-I (50 g) was incubated for 3 hours at 37°C with a mouse mast cell lysate (15 units/10 000 mast cells) or recombinant human chymase (Teijin Ltd, Japan, 80 units/g) in 5 mM Tris-HCI containing 150 mM NaCI, 1 mM EDTA (pH 7.4) providing increasing chymotryptic activities. Aliquots of the chymase-treated preparations were applied to SDS-PAGE, and human apoA-I was detected by Western blotting. Proteolytic fragments are highlighted in representative gels. B, Human apoA-I was incubated with increasing concentrations of the mouse mast cell lysate as described above, and the generated fragments were visualized by Western blotting (see arrows in gel shown at top). Aliquots of these chymase-treated apoA-I preparations were added to cultured [ 3 H]CE-labeled mouse peritoneal macrophage foam cells (final concentration of apoA-I in medium, 10 g/mL) (bottom). After 4 hours of incubation, efflux of cholesterol was determined and expressed as dpm medium /(dpm cells ϩdpm medium )ϫ100. Values are meansϮSD of triplicate wells.
this purpose, we incubated human apoA-I with increasing mouse chymase activities, starting with 18 U of chymase, which corresponds to Ϸ10% of the activity present in the total population of peritoneal mast cells in the mouse, 10 and which leads to total loss of intact apoA-I, as confirmed by Western blotting (Figure 1B, top) . Importantly, when these chymase-treated preparations were added to macrophage foam cells in which the ABCA1-mediated pathway is upregulated, 18 their ability to promote cholesterol efflux was almost totally blunted ( Figure 1B , black bars). These results revealed that mouse chymase had functionally inactivated human apoA-I, possibly by truncating its C-terminal region analogous to the human chymasedependent inactivation mechanism. 13 
In Vivo Proteolytic Inactivation of Human ApoA-I by Mouse Chymase
Next, we tested whether the function of human apoA-I as an acceptor of macrophage cholesterol would be impaired in vivo when peritoneal mast cells were stimulated to degranulate and, thus, to secrete chymase. Importantly, mouse chymase is partially resistant to protease inhibitors found in the peritoneal fluid. 10 Mice received a single intraperitoneal dose of 48/80 to activate peritoneal mast cells (stimulated mice) or saline (nonstimulated mice), immediately followed by a single intraperitoneal dose of human apoA-I. A third group of mice received only saline in the 2 injections (control group). After 3 hours, peritoneal fluid was collected, and its ability to promote cholesterol efflux from cultured macrophage foam cells was then evaluated ex vivo in macrophage foam cell cultures. Initially, we injected a high dose of apoA-I (15 mg/kg) into the peritoneal fluid of mice that had been treated with either 0.5 or 1 mg/kg of 48/80, and we observed a dose-dependent, significant (Pϭ0.038 for trend) inhibitory effect on cholesterol efflux ( Figure 2A ). Next we reduced the apoA-I dose to 3 mg/kg, which was found to also increase the cholesterol acceptor competence of peritoneal fluid, and found that pretreatment with 48/80 fully suppressed the apoA-I stimulatory effect ( Figure 2B ). These dose-response studies strongly suggested that the neutral protease chymase released by degranulated mast cells into the peritoneal fluid had proteolytically inactivated human apoA-I in the peritoneal cavity, thereby nullifying its ability to act as a cholesterol acceptor ex vivo. Because the 3 mg/kg dose of human apoA-I maintained an increased efflux-inducing ability of peritoneal fluid for at least 3 hours, we predicted that under these conditions the in vivo transfer of peritoneal macrophage cholesterol to the intestinal lumen might also proceed at an accelerated rate and could be measured within this period of time. Moreover, the ex vivo efflux results strongly suggested that pretreatment of the mice with the 1 mg/kg dose of 48/80 would block the overall apoA-I effect. These doses were therefore selected for the following RCT experiments.
Validation of Short-Time RCT Assay From Intraperitoneally Injected Macrophages to Intestinal Lumen Contents
To study the in vivo effect of peritoneal mast cell degranulation on the rate of RCT, we adapted an established macrophage-specific RCT assay. 15 This RCT assay evaluates the transfer of [ 3 H]cholesterol from macrophages injected into the peritoneal cavity to feces within periods of 24 or 48 hours, and it has been widely applied in genetically modified mice. 19, 20 Given the relatively short period of our in vivo incubation model, we first evaluated the reliability of the RCT assay when the time between the intraperitoneal injection of labeled macrophages and the collection of samples was shortened to 3 or 6 hours (Supplemental Figure I ). Within these time limits, the assay proved to be an accurate measure of the time-dependent transfer of macrophage radioactivity to plasma and intestinal lumen contents, even within the 3-hour time frame. We then evaluated whether the modified assay would be sufficiently sensitive to measure changes in the Figure 2 . In vivo mast cell-dependent proteolytic inactivation of human apoA-I. Mice were given intraperitoneal injection of 48/80 to promote mast cell degranulation (stimulated group) or saline (nonstimulated group), immediately followed by intraperitoneal injection of human apoA-I. Another group of mice received only saline in both injections (control group). Mice received either high (A) or low (B) doses of human apoA-I, and peritoneal mast cells were stimulated by doses of 48/80 (either 0.5 or 1 mg/kg). At 3 hours postinjection, mice were euthanized and peritoneal fluid was collected and pooled for each group. Efflux of cholesterol from cultured [ 3 H]CE-labeled mouse peritoneal macrophage foam cells to mouse peritoneal fluid (v/v, final concentration in medium, 2.5%) was determined as described in Figure 1B legend. To denote the specific efflux increase attributed to human apoA-I, a shadow area labels basal cholesterol efflux level stimulated by peritoneal fluid from control mice. Values are meansϮSD of triplicate wells. Statistical significance was determined by 1-way ANOVA with the Tukey multiple comparison test. Five mice were used in each experimental group. ANOVA for trend analysis rendered a significant difference for the used doses and efflux responses (A) (Pϭ0.038).
RCT efficiency induced within this relatively short time. Because activation of liver X receptor significantly increases macrophage-derived [ 3 H]cholesterol tracer contents in feces, 21, 22 we injected labeled macrophages into the peritoneal cavity of mice treated with the liver X receptor agonist T0901317 and measured [ 3 H]tracer levels in plasma, liver, and intestinal contents after 3 hours. In line with previous results, 21 even though liver X receptor activation did not affect plasma or liver [ 3 H]cholesterol levels, the [ 3 H]tracer transfer to the intestinal lumen contents increased Ϸ2-fold compared with control mice (Supplemental Figure II) . Overall, application of the 3-hour macrophage RCT assay appeared to be valid for quantification of cholesterol efflux from peritoneal macrophages to the intestinal contents, and so it could be applied to our experimental model in which mast cell-derived proteolysis of a single dose of human apoA-I is acutely triggered in the peritoneal cavity.
Effect of Mast Cell Degranulation on In Vivo RCT Stimulated by Human ApoA-I
To test our hypothesis on the in vivo mast cell proteolytic inactivation of RCT, we evaluated RCT in both stimulated (48/80-treated) and nonstimulated mice that received intraperitoneal injection of human apoA-I (3 mg/kg) and in control mice that received saline only. The experimental protocol was identical to that described in Figure 2 , but in addition, [ 3 H]cholesterol-labeled J774 macrophages were administered together with apoA-I during the second injection. Three hours after injection of the macrophages, we collected blood, liver, and total intestinal lumen contents and measured [ 3 H]tracer radioactivity of the samples (Figure 3 ). We found that compared with the control group, the levels of [ 3 H]cholesterol in plasma were reduced both in the nonstimulated and in the stimulated group, whereas the [ 3 H]tracer levels in liver were similar in all 3 groups of mice ( Figure 3A and 3B). More importantly, the [ 3 H](cholesterolϩbile acids) radioactivity in intestinal lumen contents was significantly higher in the nonstimulated mice ( Figure 3C ). This indicated that the intraperitoneally injected human apoA-I increased the transfer of macrophage-derived cholesterol to the intestinal lumen, most likely by promoting ABCA1-dependent cholesterol efflux from the J774 cholesterol-laden macrophages. In sharp contrast, the apolipoprotein stimulus on RCT was completely blocked in 48/80-treated mice, ie, in mice in which peritoneal mast cells had been activated ( Figure 3C ).
To clarify the mechanism underlying RCT inhibition by 48/80, we evaluated the 48/80 effect on the mRNA expression of J774 macrophage cholesterol transporters in vitro and found that a 3-hour incubation with 48/80 did not change the gene expression levels of ABCG1 or SR-BI but did increase that of ABCA1 (Supplemental Figure III) . This finding suggested that in the 48/80-treated mice, the observed inhibitory effect on RCT was not attributed to inhibition of ABCA1 transporter but rather to inhibition of the ligand of this transporter (ie, apoA-I). The overall results concurred with the notion that exocytosed chymase released from 48/80-activated peritoneal mast cells had degraded human apoA-I in the peritoneal cavity, thus impairing the ABCA1-dependent cholesterol efflux from the coinjected macrophages and ultimately leading to diminished transfer of cholesterol from the peritoneal cavity to the intestinal lumen.
To ascertain that activation of peritoneal mast cells was responsible for the attenuated transfer of macrophage-derived cholesterol to the intestinal lumen, we repeated the above RCT experiment using genetically mast cell-deficient sash mice. Trends similar to those found in the wild-type mice were observed for the [ 3 H]cholesterol levels in plasma and liver ( Figure 3D and 3E) . In sharp contrast, [ 3 H]tracer levels were significantly increased in the intestinal lumen in both groups relative to the control group ( Figure 3F ), indicating that the compromised RCT rate in the 48/80-treated wild-type mice ( Figure C) was mast cell dependent.
In the course of the above RCT experiments, we found that the levels of [ 3 H]cholesterol in plasma and liver did not follow a consistent trend when related to the net transfer of [ 3 H]cholesterol from macrophages to the intestine (see Figure  3 and Supplemental Figure II ). This lack of association between [
3 H]cholesterol levels in plasma, liver, and feces has also consistently been observed by others when using the original RCT assay of 24/48 hours' duration. [21] [22] [23] [24] Because plasma and liver are transit compartments for cholesterol from the peritoneal cavity to feces, it appeared that they only incompletely reflected the rate of the whole RCT process at any single given time point, thus giving a poor readout also in the present 3-hour in vivo RCT assay. It is likely that in our model, the intermediate RCT steps were also modulated by restoration of homeostasis, which followed the temporary burst of RCT, whereas a cumulative effect was clearly observed in the cholesterol transfer to the intestinal lumen.
Validation of the Mast Cell-Derived Proteolytic Inhibitory Effect on In Vivo RCT
To validate that proteolysis of the injected human apoA-I was responsible for the observed RCT inhibition, we next applied the 3-hour RCT assay in mice that received intraperitoneally a human apoA-I preparation that had been preincubated for 3 hours in the absence (control) or presence (proteolyzed) of mouse chymase. Such proteolyzed apoA-I is not competent in promoting cholesterol efflux in vitro ( Figure 1B) . Similarly, the preproteolyzed apoA-I was not able to stimulate the transfer of the tracer to intestine (Figure 4 ). This finding further strengthened the notion that declined RCT in mice in which peritoneal mast cells had been stimulated by 48/80 was caused by chymase-dependent proteolysis of the intact human apoA-I.
We further evaluated RCT in 48/80-stimulated mice that received a type of cholesterol acceptor that is not susceptible to proteolysis. This was assessed by intraperitoneal injection of cholesterol-free phospholipid vesicles, which are efficient inductors of aqueous diffusion of cellular cholesterol. 25 For this purpose, we injected intraperitoneal phosphatidyl choline as small unilamellar vesicles to nonstimulated and 48/80-stimulated mice. Phosphatidyl choline as small unilamellar vesicles (30 mg/kg) significantly increased the transfer of [ 3 H]cholesterol to intestine, and importantly, activation of peritoneal mast cells totally failed to alter the rate of RCT (Figure 4) . Together, these results provided strong evidence that decline of RCT in vivo in 48/80-treated wild-type mice ( Figure 3C ) was mediated by mast cell-dependent proteolytic degradation of human apoA-I rather than by other consequences of mast cell activation.
We also examined the effect of 48/80 (1 mg/kg) on the basal RCT component covered by the endogenous cholesterol acceptor system, ie, in the absence of exogenously administered human apoA-I, and found similar magnitudes of RCT in the 2 groups of mice (Figure 4) . Considering the present model of local mast cell activation, this finding might reflect a lower in vivo efficiency of chymase in degrading mature ␣-HDL species, as it has been found in vitro. 17 Indeed, mouse apoA-I in the peritoneal fluid exists predominantly (Ϸ80%, own measurements) as ␣-migrating species and is constantly supplied from plasma.
ApoA-I in Peritoneal Fluid
To better assess the metabolic fate of intraperitoneally injected human apoA-I, we analyzed human apoA-I concentrations in the peritoneal fluid at different time points after mast cell stimulation. The results revealed a significantly faster decay of human total apoA-I in stimulated compared with nonstimulated mice, and, moreover, it closely reflected the experiments, data were normalized relative to the mean value for the composite control group, which was set to 100%. Statistical significance among groups was determined by 1-way ANOVA with the Tukey multiple comparison test (4 to 6 mice were used in each experimental group).
reduction in pre-␤-HDL particles, as evaluated by 2-dimensional immunoelectrophoresis ( Figure 5A and 5B). Importantly, the decline of human apoA-I levels in the pre-␤-migrating fraction of stimulated mice was most marked within the first hour after mast cell stimulation. Accordingly, we searched for human apoA-I degradation products in peritoneal fluid derived from 48/80-stimulated mice at early stages after apoA-I administration (up to only 20 minutes). However, despite the significant reduction in total and pre-␤-migrating human apoA-I, Western blotting failed to detect any human apoA-I fragments in stimulated mice even at the shortest feasible time of collecting peritoneal fluid (3 to 5 minutes). Among the experimental groups, analysis of mouse plasma did not indicate differences in human apoA-I levels or in any other parameter studied (Supplemental Table I and Supplemental Figure V) .
Discussion
Although mast cell degranulation leads to massive release of active proteases to the extracellular environment, its potential role to modify RCT by degrading apolipoproteins in vivo has not been studied before. In the present study, we demonstrate that targeted activation of mast cells in the peritoneal cavity of mice from which RCT was accelerated by a single dose of human apoA-I was sufficient to fully block the in vivo apolipoprotein-mediated stimulation of macrophage RCT. This inhibitory effect was mast cell-dependent because administration of the mast cell-specific degranulating compound 48/80 to human apoA-I-treated mast cell-deficient sash mice did not compromise the RCT. Moreover, the inability of activated peritoneal mast cells to affect RCT rate in mice that received an intraperitoneal injection of phospholipid vesicles further suggested that proteolysis was the mechanism involved, by which mast cells reduced human apoA-I-induced macrophage RCT in vivo.
As in the peritoneal cavity, mast cells and macrophages coexist in the arterial wall. Because both peritoneal and intimal fluids are filtrates from blood plasma, the levels of HDL particles in these 2 compartments are likely to be similar. Therefore, the peritoneal cavity can be used as a reasonable surrogate when one studies potential effects of activated mast cells on macrophage RCT in vivo. 9 Like other extracellular fluid compartments, the peritoneal cavity is an open system from which ultrafiltration of soluble lowmolecular weight solutes through the peritoneal membrane rapidly occurs. Therefore, a rapid flux of the small 48/80 molecule (molecular mass, 520 Da) into the circulation made it unlikely that sustained activation of peritoneal mast cells had occurred. Similarly, the intraperitoneally injected apoA-I (molecular mass, 28 000 Da) can also diffuse from the peritoneal cavity, albeit at a slower filtration rate. Because of the highly dynamic nature of the cholesterol efflux assay created when peritoneal mast cells were only transitorily activated and the peritoneal fluid was acutely enriched with human apoA-I, we shortened the macrophage-specific RCT assay 15 to last only 3 hours. Importantly, the 3-hour assay was validated as reliable and sensitive to pharmacological modulation of the RCT (Supplemental Figure II) . This novel methodological application opens up further possibilities to study other short-term effects on macrophage RCT in vivo.
Consistent with the well-known apoA-I stimulatory role on the ABCA1-mediated cholesterol efflux pathway, 26 we found that a single massive intraperitoneal dose of human apoA-I (providing Ϸ100 g, ie, Ϸ10-fold the content of mouse apoA-I in the peritoneal cavity 10 ) significantly accelerated macrophage RCT. As noted above, the single dose of human apoA-I used here most likely led to only a transitory sequence of events in the peritoneal cavity. Mechanistic data on ABCA1-mediated lipidation of apoA-I indicate that pre-␤-migrating subfractions of multiple sizes are formed in vitro [27] [28] [29] . Recent in vivo studies showed that when injected intravenously, lipid-free apoA-I rapidly associates with circulating HDL, 30, 31 whereas the metabolic fate of the nascent pre-␤-HDL particles depends on their sizes. The larger the size of the pre-␤ particles, the more avidly are they taken up by the liver and the less avidly by the kidney. 31 Of note, small apoA-I/phospholipid C57Bl/6J wild-type mice were intraperitoneally injected with 48/80 or saline, followed by intraperitoneal injection of human apoA-I (3 mg/kg) as described in Figure 2B legend. After 0, 1, 2, and 3 hours of apoA-I injection, mice were euthanized, and peritoneal fluid was collected and centrifuged at 4°C at low speed to sediment detached cells. A, The contents of total human apoA-I (left) were quantitatively analyzed by ELISA in peritoneal fluid from stimulated (ϩ48/80) and nonstimulated (Ϫ48/80) mice. The levels of human apoA-I pre-␤-migrating species (percentage) (right) were analyzed by 2-dimensional immunoelectrophoresis in aliquots of same peritoneal fluid samples. Statistical significance (*PϽ0.05) among groups was determined at each time point by the Mann-Whitney U test (nϭ3 mice/group/time). B, HDL subfractions (␣ and pre-␤) in aliquots of peritoneal fluid by 2-dimensional-IE at the corresponding time points shown in A.
complexes (pre-␤ 1 -HDL) are key particles being both the early product and the substrate in the ABCA1-mediated lipid efflux reaction to apoA-I in vitro. 32 Importantly, these nascent pre-␤ 1 particles are not generated when the C-terminal ␣-helix of apoA-I is truncated. 32 Here, we found that within 1 hour of intraperitoneal administration of human apoA-I, a major fraction of it remained as pre-␤-migrating species in peritoneal fluid. It is conceivable then that in our in vivo system, the initial high concentrations of lipid-free apoA-I in peritoneal fluid provided sufficient amounts of ligand to ABCA1, generating a mixture of heterogeneous pre-␤-migrating particles, part of them with sizes competent to enable efficient transfer of macrophage cholesterol to the liver (rather than to the kidney). Because lipid-free apoA-I and pre-␤ 1 particles are highly susceptible to being functionally inactivated by chymase 33 and chymase truncates human apoA-I at the C-terminal region, 17 it follows that degranulation of mast cells and ensuing release of chymase can suppress an apoA-I-mediated RCT stimulatory effect. This notion is supported by the sharp decay found in human apoA-I pre-␤-migrating species in peritoneal fluid of the stimulated mice (within 1 hour; see Figure 5A ), which was associated with the reduced transfer of macrophage-derived cholesterol to the intestinal lumen (within 3 hours; see Figure  3C ).
Although dysfunctional HDL has been found during systemic activation of mast cells in the anaphylactic mouse, 10 the small dose of 48/80 used here failed to affect the basal RCT maintained by endogenous cholesterol acceptors, at least within the limitations of this model (Figure 4) . We envision that a rapid and progressive phagocytotic removal of the exocytosed heparin-bound chymase 34 (granule phagocytosis) by the large numbers of peritoneal macrophages (both endogenous macrophages and the exogenous J774 cells) most likely restores the endogenous efflux early within the 3-hour treatment. Thus, new mouse HDL particles must have been constantly entering the peritoneal fluid while chymasecontaining granules were being removed from the peritoneal fluid, leading to progressive diminution of the mast celldependent inhibitory effect. Therefore, evaluation of the efficiency of mast cell chymase to impair the endogenous cholesterol efflux system in vivo would require another experimental setup, eg, chronic stimulation of mast cells.
The major limitation of the present work is that no proteolytic fragments of apoA-I were found in peritoneal fluid of the stimulated mice, even immediately after mast cell stimulation. The likely explanation is extremely rapid clearance of the proteolytic fragments derived from human apoA-I from the peritoneal cavity. Of note, with the use of more powerful instrumental tools, traces of human apoA-I proteolytic fragments have been detected in plasma from human subjects with inflammatory chronic conditions that may have involved activation of mast cells. 35, 36 Mast cell chymase has been shown to degrade in vitro 37 and in vivo 10 the main mouse plasma apolipoproteins that are capable of promoting high-affinity efflux of macrophage cholesterol. The present study provides validation for the concept that local extracellular proteolysis of apolipoproteins in mouse body fluids impairs the in vivo initiation of macrophage-specific RCT. In contrast, the phospholipidstimulated diffusional cholesterol efflux that also significantly promoted RCT was not inhibited by mast cell activation. Additional studies in suitable animal models are required to assess whether activation of the proteasecontaining mast cells in the atherosclerotic arterial wall would reduce the efflux of macrophage cholesterol promoted by the actual blend of acceptors present in the intimal fluid and so attenuating the initiation of the RCT pathway from vulnerable lesions to ultimate excretion of cholesterol from the body.
